Safety Considerations for Intraoperative Use of Cytostatic Agents

Summary1. Separated leukocytes or total blood from normal subjects, untreated leukaemic patients and from leukaemic patients treated with cytostatic agents were incubated with CH3COONa-l-C14. Radioactivity of mixed lipids was measured at standard time intervals.2. The time incorporation curve observed with leukocytes from treated leukaemic patients showed after an initial linear part, a more rapid levelling off than the curves observed with leukocytes from untreated and normal subjects.3. Therefore, an indirect effect of treatment on leukocyte lipid synthesis seems to be present.4. Phospholipid and neutral lipid synthesis by leukaemic leukocytes was also studied. The results give no evidence that these fractions as a whole have any precursor-product relation.

Download Full-text

Requirements & safety considerations for a laser lab in an educational institution

International Laser Safety Conference ◽

10.2351/1.5056424 ◽

1997 ◽

Author(s):

Prem Batra

Keyword(s):

Educational Institution ◽

Safety Considerations

Download Full-text

Dental Development in Children After Chemotherapy

Revista de Chimie ◽

10.37358/rc.17.6.5681 ◽

2017 ◽

Vol 68 (6) ◽

pp. 1397-1400

Author(s):

Cristina Bica ◽

Mihaela Chincesan ◽

Daniela Esian ◽

Krisztina Martha ◽

Valentin Ion ◽

...

Keyword(s):

Acute Lymphoblastic Leukemia ◽

Tooth Development ◽

Lymphoblastic Leukemia ◽

Treatment Method ◽

Paediatric Oncology ◽

Structural Defects ◽

Dental Development ◽

Cytostatic Agents ◽

Dental Abnormalities ◽

Tooth Buds

Chemotherapy, as a treatment method in paediatric oncology, coincides with the physiological process of tooth development. The interference between cytostatic agents and the cycle of the cells with specialised functions in the formation and mineralisation of dental structures leads to the appearance of abnormalities in the development of the tooth buds, structural defects and disorderly eruption. We have looked into the distribution of developmental tooth disorders in a group of children suffering from malignant ailments. The study reveals a high occurrence of microdontia and agenesis of premolars among children diagnosed with high-risk acute lymphoblastic leukemia at the age between 1 and 6, as well as tooth eruption disturbances in 70% of the children. The nature and the severity of dental abnormalities depend on the type of cytostatic medication, the dosage and the frequency of therapeutic cycles, the age of the child at the beginning of the oncological therapy, as well as on the stage of the odontogenesis.

Download Full-text

ANTIBODY-DRUG CONJUGATES FOR TARGETED CANCER THERAPY

Problems in oncology ◽

10.37469/0507-3758-2019-65-6-777-784 ◽

2019 ◽

Vol 65 (6) ◽

pp. 777-784

Author(s):

David Korman

Keyword(s):

Clinical Trials ◽

Clinical Practice ◽

Gemtuzumab Ozogamicin ◽

Brentuximab Vedotin ◽

Cytostatic Agent ◽

Cytostatic Agents ◽

Drug Conjugates ◽

Natural Substances ◽

Intracellular Release ◽

High Antitumor Activity

Monoclonal antibody (MAB) conjugates with cytostatic agents (ADC) are intended for selective delivery of a cytostatic agent to a tumor cell. Three ADC have been approved for clinical use (gemtuzumab ozogamicin, brentuximab vedotin, trastuzumab-DM1); a few dozens of other ADC are undergoing clinical trials. Several derivatives of natural substances (antibiotics and inhibitors of microtubules) having a high antitumor activity are used as cytostatic agents included in ADC. They are inapplicable in clinical practice as self-sustained drugs due to their considerable toxicity. Of great importance for the implementation of the ADC effect is the character of a linker connecting MAB with a cytostatic agent and ensuring selective intracellular release after ADC internalization. The structure, mechanisms of action, and the results of clinical trials of a number of ADC are considered here as an illustration (by way of example). The development of ADC can help introduce new effective cytostatic agents into clinical practice.

Download Full-text

Lead removal from drinking water - development and validation of point-of-use treatment devices

Water Science & Technology Water Supply ◽

10.2166/ws.2002.0171 ◽

2002 ◽

Vol 2 (5-6) ◽

pp. 209-216

Author(s):

R. Sublet ◽

A. Boireau ◽

V.X. Yang ◽

M.-O. Simonnot ◽

C. Autugelle

Keyword(s):

Drinking Water ◽

Fixed Bed ◽

Field Testing ◽

Lead Removal ◽

Ministry Of Health ◽

Point Of Use ◽

Taste And Odor ◽

Wide Range ◽

Lead Levels ◽

Safety Considerations

Two lead removal water filters were developed to lower lead levels in drinking water below 10 μg.L-1 in order to meet the new regulation given by the European Directive 98-83, applicable in December 2013. An appropriate adsorbent was selected through a stringent research program among a wide range of media, and is composed of a synthetic zeolite and an activated carbon. Two prototypes were developed: the first is a faucet-mounted filter which contains a fixed bed of the adsorbent and a hollow fiber bundle, while the second is an under-sink cartridge made of a porous extruded block of carbon and adsorbent. Both are able to treat at least 1,000 litres of any water containing on average 100 to 150 μg Pb.L-1, by lowering the lead concentration below 10 μg.L-1. Once their safety considerations were addressed by an independent laboratory according to the French Ministry of Health recommendations, 20 prototypes were installed at consumers' taps in northeastern France. Their performance in terms of lead removal, HPC control and bad taste and odor reduction was followed for 6 months. This field testing program resulted in the validation of both prototypes which meet the new French Ministry of Health recommendations and assures that the filtered water is fully ED 98-83 compliant. Their commercialization will be launched first in France in middle 2002.

Download Full-text